Intranasal DDAVP: biological and clinical evaluation in mild factor VIII deficiency.
We report a study undertaken to test the biological effect of intranasal 1-deamino-8-D-arginine vasopressin (DDAVP) and its efficacy in the treatment of bleedings in patients with mild factor VIII deficiency. The biological study was carried out in 20 patients: an increase of factor VIII:C and von Willebrand factor antigen levels was observed after inhalation of DDAVP at average post/pre inhalation ratios of 2.80 and 1.72, respectively. No relevant alterations of fibrinolysis were noted. In fact, we only observed a simultaneous increase of tissue plasminogen activator and plasminogen activator inhibitor, without modification of D-dimer. In 10 cases intranasal DDAVP has been used in the prevention or in the treatment of bleeding complications: no bleedings were observed.
Chistolini
A
A
Section of Haematology, Department of Human Biopathology, Rome, Italy.
Dragoni
F
F
Ferrari
A
A
La Verde
G
G
Arcieri
R
R
Ege Mohamud
A
A
Mazzucconi
M G
MG
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005169:Factor VIII / Q000032:analysis; D005342:Fibrinolysis; D006467:Hemophilia A / Q000097:blood / Q000628:therapy*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged
D007155:Immunologic Factors; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin